Redhill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Growth in Short Interest

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 29,926 shares, an increase of 49.7% from the July 15th total of 19,996 shares. Based on an average daily volume of 45,467 shares, the short-interest ratio is presently 0.7 days. Currently, 0.5% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Redhill Biopharma in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Redhill Biopharma stock. Gagnon Securities LLC raised its holdings in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,102 shares of the biotechnology company’s stock after purchasing an additional 68,280 shares during the quarter. Gagnon Securities LLC owned 1.68% of Redhill Biopharma worth $89,000 as of its most recent filing with the Securities & Exchange Commission. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Stock Performance

Shares of Redhill Biopharma stock traded down $0.01 during trading hours on Tuesday, hitting $0.58. The company’s stock had a trading volume of 9,213 shares, compared to its average volume of 277,672. The business has a 50 day moving average price of $0.73 and a two-hundred day moving average price of $0.87. Redhill Biopharma has a 12-month low of $0.58 and a 12-month high of $2.79. The company has a market cap of $3.50 million, a PE ratio of 0.00 and a beta of 5.00.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.